ADVFN - Advanced Financial Network.
HOME» AMEX » P » PLX Stock Price » PLX Stock News

Protalix Biotherapeutics Share News

 Protalix Biotherapeutics, Stock Price
PLX Stock Price
 Protalix Biotherapeutics, Stock Chart
PLX Stock Chart
 Protalix Biotherapeutics, Stock News
PLX Stock News
 Protalix Biotherapeutics, Company Information
PLX Company Information
 Protalix Biotherapeutics, Stock Trades
PLX Stock Trades

FDA Accepts Protalix Resubmission For Gaucher Disease Drug; Shares Up

DOW JONES NEWSWIRES Protalix BioTherapeutics, Inc. (PLX) said the U.S. Food and Drug Administration has accepted its resubmitted new drug application for its experimental drug for Gaucher's disease, a rare genetic ailment. Protalix shares were up 4.8% at $5.01 in recent premarket trading. The stock through Tuesday's close is down 52% this year. The U.S. regulator in February had requested more data on clinical trials and on chemistry, manufacturing and controls for the experimental treatment, information the company at that time said it didn't have when it first submitted the new drug application. Protalix on Wednesday said the new submission addresses the FDA's questions, including its request for clinical data from the company's switchover trial and long-term extension trial. Gaucher's disease affects one of 20,000 live births and causes a fatty substance to develop in cells in the liver, spleen and bone marrow. Protalix is developing the product with Pfizer Inc. (PFE). The pharmaceutical giant's shares were up 7 cents at $18.38 in recent premarket trading. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Protalix Biotherapeutics (PLX)
11/23/201516:50:30Statement of Ownership (sc 13g)
11/23/201516:07:08Current Report Filing (8-k)
11/16/201507:16:13Current Report Filing (8-k)
11/16/201507:00:00Protalix BioTherapeutics to Conduct Phase III Clinical Trial...
11/13/201516:07:49Securities Registration Statement (simplified Form) (s-3)
11/10/201513:12:26Amended Statement of Ownership (sc 13g/a)
11/09/201517:41:48Quarterly Report (10-q)
11/09/201516:18:25Current Report Filing (8-k)
11/09/201516:05:00Protalix BioTherapeutics Reports Third Quarter 2015 Financial...
10/26/201507:31:18Additional Proxy Soliciting Materials (definitive) (defa14a)
10/23/201515:47:53Statement of Ownership (sc 13g)
10/23/201511:09:13Amended Statement of Ownership (sc 13g/a)
10/20/201513:51:34Initial Statement of Beneficial Ownership (3)
10/19/201507:35:33Current Report Filing (8-k)
10/19/201507:30:00Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102...
10/13/201517:30:53Current Report Filing (8-k)
10/13/201507:30:00Protalix BioTherapeutics Sells Its Share in Collaboration Agreement...
10/05/201508:00:00Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis...
10/01/201516:32:24Proxy Statement (definitive) (def 14a)
09/21/201520:46:07Protalix BioTherapeutics Reports Positive Phase I/II Interim...

Protalix Biotherapeutics and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations